This company has been marked as potentially delisted and may not be actively trading. ContraVir Pharmaceuticals (CTRV) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock CTRV vs. UPC, VAXX, EVLO, CMRA, ARDS, STAB, HSTO, AMPE, CLVR, and EFTRShould you be buying ContraVir Pharmaceuticals stock or one of its competitors? The main competitors of ContraVir Pharmaceuticals include Universe Pharmaceuticals (UPC), Vaxxinity (VAXX), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Aridis Pharmaceuticals (ARDS), Statera Biopharma (STAB), Histogen (HSTO), Ampio Pharmaceuticals (AMPE), Clever Leaves (CLVR), and eFFECTOR Therapeutics (EFTR). These companies are all part of the "medical" sector. ContraVir Pharmaceuticals vs. Its Competitors Universe Pharmaceuticals Vaxxinity Evelo Biosciences Comera Life Sciences Aridis Pharmaceuticals Statera Biopharma Histogen Ampio Pharmaceuticals Clever Leaves eFFECTOR Therapeutics Universe Pharmaceuticals (NYSE:UPC) and ContraVir Pharmaceuticals (NASDAQ:CTRV) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, community ranking, valuation, media sentiment, analyst recommendations, dividends and earnings. Do insiders and institutionals believe in UPC or CTRV? 0.2% of Universe Pharmaceuticals shares are owned by institutional investors. Comparatively, 1.1% of ContraVir Pharmaceuticals shares are owned by institutional investors. 57.4% of Universe Pharmaceuticals shares are owned by company insiders. Comparatively, 1.6% of ContraVir Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the MarketBeat Community prefer UPC or CTRV? ContraVir Pharmaceuticals received 219 more outperform votes than Universe Pharmaceuticals when rated by MarketBeat users. CompanyUnderperformOutperformUniverse PharmaceuticalsN/AN/AContraVir PharmaceuticalsOutperform Votes21974.49% Underperform Votes7525.51% Does the media favor UPC or CTRV? In the previous week, Universe Pharmaceuticals' average media sentiment score of 0.00 equaled ContraVir Pharmaceuticals'average media sentiment score. Company Overall Sentiment Universe Pharmaceuticals Neutral ContraVir Pharmaceuticals Neutral Is UPC or CTRV more profitable? Universe Pharmaceuticals' return on equity of 0.00% beat ContraVir Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Universe PharmaceuticalsN/A N/A N/A ContraVir Pharmaceuticals N/A -4,810.77%-130.14% Which has more risk & volatility, UPC or CTRV? Universe Pharmaceuticals has a beta of 1.51, suggesting that its stock price is 51% more volatile than the S&P 500. Comparatively, ContraVir Pharmaceuticals has a beta of 1.16, suggesting that its stock price is 16% more volatile than the S&P 500. Which has preferable valuation and earnings, UPC or CTRV? Universe Pharmaceuticals has higher revenue and earnings than ContraVir Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUniverse Pharmaceuticals$23.02M0.01-$6.16MN/AN/AContraVir PharmaceuticalsN/AN/A-$9.45MN/AN/A SummaryUniverse Pharmaceuticals beats ContraVir Pharmaceuticals on 6 of the 8 factors compared between the two stocks. Get ContraVir Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CTRV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CTRV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTRV vs. The Competition Export to ExcelMetricContraVir PharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$63K$779.99M$5.19B$8.61BDividend YieldN/A4.84%5.38%4.23%P/E RatioN/A1.1325.7419.50Price / SalesN/A224.38395.70117.29Price / CashN/A23.4435.5255.95Price / Book0.106.267.975.60Net Income-$9.45M-$26.43M$3.15B$248.44M ContraVir Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTRVContraVir PharmaceuticalsN/A$0.08+6.6%N/A-92.7%$63KN/A0.0014UPCUniverse PharmaceuticalsN/A$3.97+0.5%N/A-99.8%$171K$23.02M0.00220VAXXVaxxinityN/A$0.00-99.0%N/A-99.8%$13KN/A0.0090Gap DownEVLOEvelo BiosciencesN/A$0.00flatN/AN/A$9KN/A0.00120CMRAComera Life SciencesN/A$0.00flatN/AN/A$6K$1.00M0.002ARDSAridis PharmaceuticalsN/A$0.00flatN/A-99.9%$5K$3.09M0.0030STABStatera BiopharmaN/A$0.00flatN/A-85.7%$5KN/A0.0020HSTOHistogenN/A$0.00-94.4%N/A-99.8%$4K$19K0.0020AMPEAmpio Pharmaceuticals0.1303 of 5 stars$0.00-97.7%N/A-97.9%$3KN/A0.0020High Trading VolumeCLVRClever LeavesN/A$0.00flatN/A-100.0%$1K$17.42M0.00560EFTReFFECTOR TherapeuticsN/A$0.00flatN/A-99.9%$1K$3.55M0.0010 Related Companies and Tools Related Companies Universe Pharmaceuticals Competitors Vaxxinity Competitors Evelo Biosciences Competitors Comera Life Sciences Competitors Aridis Pharmaceuticals Competitors Statera Biopharma Competitors Histogen Competitors Ampio Pharmaceuticals Competitors Clever Leaves Competitors eFFECTOR Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CTRV) was last updated on 6/25/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ContraVir Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share ContraVir Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
